Medite Cancer Diagnostics Stock Analysis
| MDIT Stock | USD 0.0001 0.00 0.00% |
Medite Cancer Diagnostics holds a debt-to-equity ratio of 0.94. Medite Cancer's financial risk is the risk to Medite Cancer stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Medite Cancer's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Medite Cancer's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Medite Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Medite Cancer's stakeholders.
For many companies, including Medite Cancer, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Medite Cancer Diagnostics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Medite Cancer's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Medite Cancer's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Medite Cancer is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Medite Cancer to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Medite Cancer is said to be less leveraged. If creditors hold a majority of Medite Cancer's assets, the Company is said to be highly leveraged.
Medite Cancer Diagnostics is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Medite Cancer pink sheet analysis is to determine its intrinsic value, which is an estimate of what Medite Cancer Diagnostics is worth, separate from its market price. There are two main types of Medite Cancer's stock analysis: fundamental analysis and technical analysis.
The Medite Cancer pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Medite |
Medite Pink Sheet Analysis Notes
The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medite Cancer Diagnostics recorded a loss per share of 0.11. The entity last dividend was issued on the 29th of October 2010. The firm had 1:100 split on the 12th of March 2015. Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.The quote for Medite Cancer Diagnostics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Medite Cancer Diagnostics contact the company at 407-996-9630 or learn more at https://medite-group.com.Medite Cancer Diagnostics Investment Alerts
| Medite Cancer generated a negative expected return over the last 90 days | |
| Medite Cancer has some characteristics of a very speculative penny stock | |
| Medite Cancer has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (6.81 M) with profit before overhead, payroll, taxes, and interest of 162 K. | |
| Medite Cancer Diagnostics currently holds about 90 K in cash with (3.57 M) of positive cash flow from operations. |
Medite Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 520.34 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medite Cancer's market, we take the total number of its shares issued and multiply it by Medite Cancer's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Medite Profitablity
The company has Profit Margin (PM) of (0.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.49.Technical Drivers
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medite Cancer Diagnostics, as well as the relationship between them.Medite Cancer Diagnostics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Medite Cancer price series with the more recent values given greater weights.
Medite Cancer Outstanding Bonds
Medite Cancer issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medite Cancer Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medite bonds can be classified according to their maturity, which is the date when Medite Cancer Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US58506YAS19 Corp BondUS58506YAS19 | View | |
| MEDTRONIC INC 4375 Corp BondUS585055BT26 | View | |
| MEDTRONIC INC 4625 Corp BondUS585055BU98 | View | |
| US58502BAE65 Corp BondUS58502BAE65 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Medite Cancer Diagnostics Debt to Cash Allocation
Medite Cancer Diagnostics currently holds 4.91 M in liabilities with Debt to Equity (D/E) ratio of 0.94, which is about average as compared to similar companies. Medite Cancer Diagnostics has a current ratio of 1.09, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Medite Cancer until it has trouble settling it off, either with new capital or with free cash flow. So, Medite Cancer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medite Cancer Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medite to invest in growth at high rates of return. When we think about Medite Cancer's use of debt, we should always consider it together with cash and equity.Medite Cancer Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Medite Cancer's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Medite Cancer, which in turn will lower the firm's financial flexibility.Medite Cancer Corporate Bonds Issued
About Medite Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Medite Cancer prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Medite shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Medite Cancer. By using and applying Medite Pink Sheet analysis, traders can create a robust methodology for identifying Medite entry and exit points for their positions.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Medite Cancer to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.